DIABETES AND CANCER

The association between type 2 diabetes diagnosis and diabetes medications with risk of cancer

Coordinatore	UNIVERSITY OF IOANNINA    more  Organization address address: "LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON" city: IOANNINA postcode: 45110 contact info Titolo: Mr. Nome: Georgios Cognome: Detsikas Email: send email Telefono: +30 26510 07134 Fax: +30 26510 07967
Nazionalità Coordinatore	Greece [EL]
Totale costo	157˙720 €
EC contributo	157˙720 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2010-IEF
Funding Scheme	MC-IEF
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-09-01   -   2013-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF IOANNINA  Organization address address: "LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON" city: IOANNINA postcode: 45110 contact info Titolo: Mr. Nome: Georgios Cognome: Detsikas Email: send email Telefono: +30 26510 07134 Fax: +30 26510 07967	EL (IOANNINA)	coordinator	157˙720.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Type 2 diabetes and cancer are two chronic diseases that negatively influence the survival of millions of people worldwide. Diabetes has been shown in meta-analyses to be associated with an increased risk of several cancers, but these associations are not yet documented as causal. The evidence for specific diabetes drugs affecting cancer risk is limited, because randomized clinical trials are not designed to evaluate specifically cancer outcomes, and observational studies are often confounded by indications for specific drugs. We propose to better characterize the degree of involvement of type 2 diabetes diagnosis and pharmacologic treatment in cancer initiation or progression. Therefore, we will a) evaluate bias and credibility in the existing meta-analyses of diabetes diagnosis and cancer risk, b) determine whether diabetes diagnosis is associated with risk of prostate cancer using the European Prospective Investigation into Cancer and Nutrition cohort, c) perform a systematic review and meta-analysis of randomized clinical trials and observational studies that have evaluated the association between diabetes medications and cancer risk, and d) evaluate the association between diabetes drugs and cancer risk (separately by site) using the UK-based General Practice Research Database. Cutting-edge evidence synthesis methods (Harbord’s test, excess significance bias test, credibility ceilings) will be used in our first aim, and summary meta-analytic estimates will be calculated in our third aim using random effects models. An incident diabetes drug cohort design with adherence-adjusted intention-to-treat style of analysis will be used in aim 4, while Cox proportional hazards models will be used in both aims 2 and 4. The proposed project will have major impact in the field, because the literature on diabetes diagnosis, treatment on cancer risk will be properly evaluated, and these associations will be further assessed in two large, unique prospective studies.'

Introduzione (Teaser)

Type 2 diabetes (T2d) and cancer are two chronic diseases that affect millions of people worldwide. Even a weak association of diabetes diagnosis or diabetes medications with the risk of cancer may have important public health consequences.